Glioma clinical trials in Texas
26 studies for Glioma are looking for participants at sites in Texas.
Cities in Texas
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Houston
- Research Site, San Antonio
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Oct 5, 2026 · NCT05417594A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- and 8 more
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Oct 1, 2026 · NCT05099003MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
- M D Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03896568A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
- Baylor College of Medicine, Houston
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Texas Children's Hospital, Houston
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated Sep 21, 2026 · NCT06838676MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas
- M D Anderson Cancer Center, Houston
Recruiting
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04373720Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
- M D Anderson Cancer Center, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04771806Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
- The University of Texas M. D. Anderson Cancer Center, Houston
RecruitingPhase 1
36 Months · All sexes · Updated Sep 9, 2026 · NCT07076498Targeted Pediatric High-Grade Glioma Therapy
- Texas Children's Hospital, Houston
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388Study of Olutasidenib and Temozolomide in HGG
- Texas Children's Hospital, Houston
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- University of Texas Health Mays Cancer Center, San Antonio
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Texas Children's Hospital, Houston
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- M D Anderson Cancer Center, Houston
RecruitingObservational study
All ages · All sexes · Updated Aug 21, 2026 · NCT01772771Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- University Of Texas Southwestern Medical Center, Dallas
RecruitingPhase 1
Ages 1 to 25 · All sexes · Updated Aug 18, 2026 · NCT04485559Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
- Excel Diagnostics & Nuclear Oncology Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT07733674C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
- Texas Children's Hospital, Houston
RecruitingPhase 1
12 Months – 25 Years · All sexes · Updated Aug 3, 2026 · NCT04099797A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Texas Children's Hospital, Houston
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
- M D Anderson Cancer Center, Houston
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT05804227Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Texas Children's Hospital, Houston
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06326411Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06810544A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Texas Children's Hospital, Houston
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
- The Cancer Therapy and Research Center at UTHSCSA, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 30, 2025 · NCT05460507Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- UT Southwestern Medical Center, Dallas
- The Cancer Therapy and Research Center at UTHSCSA, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 26, 2025 · NCT01906385From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.